EP Patent

EP1962827A2 — Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

Assigned to Merck Sharp and Dohme LLC · Expires 2008-09-03 · 18y expired

What this patent protects

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: EP1962827A2
Jurisdiction: EP
Classification: —
Expires: 2008-09-03
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.